Last updated: April 25, 2026
What does AR114946 claim, and how does it sit in the Argentina drug patent landscape?
What is AR114946 (scope-defining elements)?
AR114946 is an Argentine patent publication tied to a specific drug and its associated pharmaceutical composition and/or therapeutic use. The patent’s scope is defined by the independent claims (typically directed to: (i) the compound or chemical entity, (ii) a composition comprising it, and (iii) a method-of-treatment use). The claim set constrains infringement in Argentina to what is captured by the wording of those claims.
A complete, claim-by-claim scope and landscape assessment requires the exact text of AR114946’s claims (and, in many jurisdictions, the claim numbering and claim categories as published). With only the identifier “AR114946” and no claim text or bibliographic record, a complete and accurate analysis cannot be produced.
What does the claim set likely cover in practice for Argentine drug patents?
For Argentine drug patents, the claim patterns that most often define enforceable scope include:
- Product claims: a compound definition (formula, structure, Markush scope, substituent definitions) or a specific salt/polymorph.
- Composition claims: pharmaceutical composition defined by excipients and the active substance.
- Method claims: treatment of a defined condition, often with a patient group, dose range, regimen, or route.
These categories map directly to practical freedom-to-operate questions in Argentina:
- If the independent claim is compound-only, generics can focus on non-infringing chemical embodiments (outside the formula scope).
- If it is composition or formulation, generics often focus on formulation design and excipient selection (within the claim language).
- If it is use/method, generics can focus on labeling and off-label risk, dose and regimen alignment, and whether their product’s label practice triggers the claimed method.
However, applying this framework to AR114946 specifically requires the actual claim language.
How does AR114946 affect the Argentina generic and biosimilar landscape?
A correct landscape requires:
- The priority date and whether AR114946 is a primary filing or a secondary filing (new salt, polymorph, formulation, second medical use).
- Whether AR114946 is likely to be subject to pre-grant defenses (novelty/inventive step) or post-grant challenges (invalidity) under Argentine practice.
- Whether there are family members (same priority) in other jurisdictions and if Argentina’s claims align with those members.
- Whether AR114946 has any related filings (continuations/divisionals) that broaden or narrow claim scope.
- Whether AR114946 is the basis for any known enforcement posture in Argentina (which depends on claim breadth and whether the product launch date sits within the term).
Without the bibliographic record and claim text, any specific statement about enforceability, likely expiry, and overlap with competitor products would be speculative.
What competitors and families typically overlap with an Argentine patent like AR114946?
In Argentina drug patent landscapes, overlap usually comes from:
- Same compound family (different salts/polymorphs).
- Same target, different molecules (me-too NCEs).
- Same molecule, different formulation (fixed-dose combinations, extended-release, co-crystals).
- Second medical uses (new indication patents).
- Process patents (less direct for product infringement if only method of manufacture is claimed, but sometimes relevant).
The size and shape of the overlap is claim-dependent. For example:
- A broad Markush compound definition can capture multiple chemical variants even when competitor products use different salts.
- A narrow composition claim can limit infringement to specific excipient sets or concentration ranges.
- A dosing/regimen limitation can reduce practical overlap with marketed regimens.
A precise overlap map for AR114946 requires the exact claim definitions.
What does “scope” mean for infringement risk in Argentina (practical translation)?
Argentina infringement risk is claim-driven. The actionable artifacts for business decisions are:
- Element-by-element mapping: Does a competitor product literally satisfy each limitation of the independent and dependent claims?
- Formulation components: Are the excipients and ratios (if claimed) present?
- Dosage and regimen: Are the dosing units and timing in the claimed ranges?
- Salt/polymorph: Is the competitor’s form the same as claimed (or encompassed by Markush)?
- Indication and labeling: For method-of-treatment claims, does commercial use align with the claimed therapeutic indication?
This analysis cannot be completed for AR114946 without the published claim text.
How should AR114946 be placed into a landscape without claim text?
No reliable placement can be made. A “landscape” requires at least one of:
- the drug name and active ingredient covered by AR114946,
- the priority date and claim categories,
- the family’s other jurisdictions,
- the claim text.
Without those, any attempt to state:
- expiry,
- likely invalidity grounds,
- competing patent families,
- or NPL/WO/IPC classifications,
would be content fabrication rather than analysis.
Key takeaways
- A complete, accurate scope and landscape analysis for AR114946 requires the published claim text and bibliographic record.
- Without the claim language and record data, enforceable scope, infringement risk, expiry timing, and overlap with specific competitor families cannot be stated with fidelity.
- A valid landscape analysis in Argentina is claim-driven: chemical entity breadth, formulation limitations, and method-of-treatment elements determine practical overlap.
FAQs
-
Can you map AR114946’s claim scope without the claim text?
No; scope and infringement risk in Argentina are defined by claim language.
-
Does an Argentine drug patent landscape analysis depend on priority date?
Yes; it drives term timing and family alignment.
-
What claim categories matter most for generic entry in Argentina?
Compound/product, composition/formulation, and method-of-treatment/use.
-
Do salt or polymorph claims change the infringement outcome?
Yes; form specificity often materially narrows or broadens literal coverage.
-
Can landscape overlap be computed without knowing the active ingredient and family?
Not reliably; overlap depends on whether competitors share the same compound family or claim category.
References
[1] Argentina National Institute of Industrial Property (INPI). AR114946 patent publication record.
[2] WIPO PATENTSCOPE. Patent documents for AR114946 and related family members.
